Q32 Bio Inc.

NASDAQ:QTTB

Biotechnology

Healthcare
$8.53 -1.70%

-$0.22 today

Market cap
$255.25M
Beta
-0.23
P/E (TTM)
5.4
EPS (TTM)
$2.36
52W Low $1.35High $14.85

Volume 0.26M

Average 0.74M

QTTB Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Q32 Bio Inc.NASDAQ: QTTB

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 14.1M shares rose 15.6% year over year, ahead of the +5.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 12.2% from the prior quarter. Over 3 fiscal years it compounded at +56.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +15.6% holds above the trailing-twelve-month pace of +5.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
14.1M+12.2% QoQ
Last fiscal yearDec 2025
12.3M+0.8% YoY
LTMMar 2026
12.77M+5.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.6%——
1 year+0.8%——
3-year CAGR+56.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
12.3M USD
Year-over-year change
+0.8%
4-year CAGR
+41.5%

Weighted Avg Shares vs competitors

How QTTB compares with its peers on the latest reported figures

  • QTTB's LTM Mar 2026 weighted avg shares of 12.77M shares is the 4th highest of the 5 companies compared; the peer median is 26.78M shares.
  • Its year-over-year change of +5.5% is the 4th highest of 5, against a peer median of +32.4%.
  • Over three fiscal years its annual growth of +56.8% compares with a peer median of +35.7%.
QTTB Competitors Peer median
Weighted Avg Shares for QTTB and competitors
Company Period LTM YoY 3-year CAGR
SABSSAB Biotherapeutics, Inc.LTM Jun 202640.82M +340.0%+64.3%
ANTXAN2 Therapeutics, Inc.LTM Mar 202631.18M +4.3%+25.4%
BOLDBoundless Bio, Inc.LTM Mar 202622.38M +7.1%+0.2%
QTTBQ32 Bio Inc.LTM Mar 202612.77M +5.5%+56.8%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 202610.07M +57.7%+46.1%
Peer median (excluding QTTB) 26.78M+32.4%+35.7%

Competitors are the stored peer set for QTTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.97M6.65M(6.65M)053.74M
Cost of Revenue9.54M2.6M499K487K391K
Gross Profit24.43M6.65M(6.65M)(487K)53.35M
Gross Margin71.9%100.0%100.0%—99.3%
Research & Development93.09M35.81M31.73M48.14M19.16M
Selling, General & Admin27.29M10.06M9.88M17.47M17.68M
Operating Expenses120.38M45.88M41.6M65.61M36.44M
Depreciation & Amortization9.54M370K499K487K391K
EBITDA(86.22M)(38.86M)(47.76M)(45.3M)17.29M
EBITDA Margin-253.8%-584.2%718.0%—32.2%
Operating Income(95.95M)(39.23M)(48.26M)(66.1M)16.9M
Operating Margin-282.4%-589.8%725.5%—31.5%
Interest Income185K3.23M03.9M2.2M
Interest Expense000300K1.1M
Other Income / Expenses185K(3.52M)(5.17M)18.39M12.92M
Income Before Tax(95.76M)(42.75M)(53.43M)(47.71M)29.82M
Pre-Tax Margin-281.9%-642.7%803.3%—55.5%
Income Tax Expense062K318K21K0
Net Income(95.76M)(42.81M)(53.74M)(47.73M)29.82M
Net Margin-281.9%-643.6%808.0%—55.5%
EPS (Basic)(31.18)(13.42)(16.70)(5.12)2.42
EPS (Diluted)(31.18)(13.42)(16.70)(6.58)2.42
Weighted Avg Shares3.07M3.19M3.22M12.2M12.3M
Weighted Avg Shares (Diluted)3.07M3.19M3.22M12.2M12.31M

Q32 Bio Inc.

NASDAQ:QTTB

Intrinsic Alpha fair value

Locked

Current Price

$8.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.